News Release

Yamanouchi Pharmaceutical Co., Ltd.

Yamanouchi Terminates Marketing Agreement on the Hypercholesterolemia Treatment Cholebine

December 1, 2004

Tokyo, Japan - December 1, 2004 - Yamanouchi Pharmaceutical Co., Ltd. (president: Toichi Takenaka) agreed with Mitsubishi Pharma Corporation (president: Takeshi Komine) on termination of the marketing agreement on the hypercholesterolemia treatment Cholebine (colestimide) following its expiration on March 31, 2005. At present, this product is being comarketed by the two companies. On April 1, 2005 and onward, it will be independently marketed by Mitsubishi Pharma Corporation.

The products whose marketing will be terminated by Yamanouchi following termination of the agreement are as shown below. Sales of these products by Yamanouchi in the fiscal year ending March 2004 were about 1.5 billion yen.

Cholebine Tablet500mg
Cholebine Mine83%